Adaptimmune Therapeutics plc (ADAP) |
|
8 0.02 (0.25%)
|
10-01 09:34 |
|
Open: |
7.63 |
Pre. Close: |
7.98 |
|
High:
|
8 |
Low:
|
8 |
|
Volume:
|
2,091 |
Market Cap:
|
1,237M |
|
|
|
|
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. The company is headquartered in Abingdon, Oxfordshire and currently employs 430 full-time employees. The firm is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The firm has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The firm engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The firm is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. The company has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8.322 - 8.368 |
8.368 - 8.411 |
|
Low:
|
7.465 - 7.522 |
7.522 - 7.574 |
|
Close:
|
7.894 - 7.98 |
7.98 - 8.059 |
|
Technical analysis |
as of: 2020-09-30 4:38:16 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 11.18 One year: 12.77 |
| Support: |
Support1: 7.37 Support2: 6.13 |
| Resistance: |
Resistance1: 9.57 Resistance2: 10.93 |
| Pivot: |
8.84  |
| Moving Average: |
MA(5): 7.82 MA(20): 8.63
MA(100): 8.66 MA(250): 4.90 |
| MACD: |
MACD(12,26): -0.18 Signal(9): |
| Stochastic oscillator: |
%K(14,3): 12.83 %D(3): 12.42 |
| RSI: |
RSI(14): 43.89 |
| 52-week: |
High: 13.40 Low: 0.71 Change(%): 523.4 |
| Average Vol(K): |
3-Month: 74664 10-Days: 60180 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.ADAP has closed above bottom band by 31.2%. Bollinger Bands are 36.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 30 Sep 2020
Is Adaptimmune Therapeutics PLC - ADR (ADAP) the Top Pick in the Biotechnology Industry? - InvestorsObserver
Tue, 29 Sep 2020
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Sees Large Increase in Short Interest - MarketBeat
Mon, 28 Sep 2020
Adaptimmune Therapeutics plc (ADAP) Bears Seem To Be Pulling The Price Back - Invest Million
Sat, 26 Sep 2020
Adaptimmune Therapeutics plc (NASDAQ:ADAP) surprises Wall Street with 1.55% stock price gain - Marketing Sentinel
Thu, 24 Sep 2020
Should You Buy Adaptimmune Therapeutics PLC - ADR (ADAP) Stock on Thursday? - InvestorsObserver
Mon, 21 Sep 2020
Bearish Stock to Watch: Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) - FXDailyReport.com
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
155 |
| Shares Float (M) |
69 |
|
% Held by Insiders
|
0.20 |
|
% Held by Institutions
|
50.74 |
|
Shares Short (K)
|
3,250 |
|
Shares Short P. Month (K)
|
3,890 |
Stock Financials |
|
EPS
|
-1.080 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
2.640 |
|
Profit Margin
|
|
|
Operating Margin
|
-5856.96 |
|
Return on Assets (ttm)
|
-21.7 |
|
Return on Equity (ttm)
|
-42.6 |
|
Qtrly Rev. Growth
|
219.7 |
|
Gross Profit (p.s.)
|
-0.623 |
|
Sales Per Share
|
0.014 |
|
EBITDA (p.s.)
|
-0.792 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-50 |
|
Levered Free Cash Flow (M)
|
-54 |
Stock Valuations |
|
PE Ratio
|
-7.39 |
|
PEG Ratio
|
|
|
Price to Book value
|
3.02 |
|
Price to Sales
|
553.27 |
|
Price to Cash Flow
|
-24.58 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
2018-03-29 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
